ARTICLE | Company News
Alexion gets fast track for complement inhibitor
February 29, 2000 8:00 AM UTC
ALXN received fast track status from the FDA for its humanized monoclonal antibody C5 complement inhibitor 5G1.1 to treat patients with membranous glomerulonephritis. The compound is in Phase II trial...